168 related articles for article (PubMed ID: 37806915)
1. Safety and Serum Estradiol Levels in Hormonal Treatments for Vulvovaginal Atrophy in Breast Cancer Survivors: A Systematic Review and Meta-Analysis.
Comini ACM; Carvalho BM; Moreira MJB; Reis PCA; Colapietro L; Northern J; Batalini F
Clin Breast Cancer; 2023 Dec; 23(8):835-846. PubMed ID: 37806915
[TBL] [Abstract][Full Text] [Related]
2. Management of postmenopausal vulvovaginal atrophy: recommendations of the International Society for the Study of Vulvovaginal Disease.
Pérez-López FR; Phillips N; Vieira-Baptista P; Cohen-Sacher B; Fialho SCAV; Stockdale CK
Gynecol Endocrinol; 2021 Aug; 37(8):746-752. PubMed ID: 34169794
[TBL] [Abstract][Full Text] [Related]
3. Safety of prasterone in breast cancer survivors treated with aromatase inhibitors: the VIBRA pilot study.
Mension E; Alonso I; Cebrecos I; Castrejon N; Tortajada M; Matas I; Gómez S; Ribera L; Anglès-Acedo S; Castelo-Branco C
Climacteric; 2022 Oct; 25(5):476-482. PubMed ID: 35343852
[TBL] [Abstract][Full Text] [Related]
4. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society.
The NAMS 2020 GSM Position Statement Editorial Panel
Menopause; 2020 Sep; 27(9):976-992. PubMed ID: 32852449
[TBL] [Abstract][Full Text] [Related]
5. Vaginal laser therapy for GSM/VVA: where we stand now - a review by the EUGA Working Group on Laser.
Salvatore S; Ruffolo AF; Phillips C; Athanasiou S; Cardozo L; Serati M;
Climacteric; 2023 Aug; 26(4):336-352. PubMed ID: 37395104
[TBL] [Abstract][Full Text] [Related]
6. The Safety of Local Hormonal Treatment for Vulvovaginal Atrophy in Women With Estrogen Receptor-positive Breast Cancer Who Are on Adjuvant Aromatase Inhibitor Therapy: Meta-analysis.
Pavlović RT; Janković SM; Milovanović JR; Stefanović SM; Folić MM; Milovanović OZ; Mamillapalli C; Milosavljević MN
Clin Breast Cancer; 2019 Dec; 19(6):e731-e740. PubMed ID: 31522958
[TBL] [Abstract][Full Text] [Related]
7. Managing Genitourinary Syndrome of Menopause in Breast Cancer Survivors Receiving Endocrine Therapy.
Sussman TA; Kruse ML; Thacker HL; Abraham J
J Oncol Pract; 2019 Jul; 15(7):363-370. PubMed ID: 31291563
[TBL] [Abstract][Full Text] [Related]
8. Treating genitourinary syndrome of menopause in breast cancer survivors: main challenges and promising strategies.
Castelo-Branco C; Mension E; Torras I; Cebrecos I; Anglès-Acedo S
Climacteric; 2023 Aug; 26(4):296-301. PubMed ID: 36946290
[TBL] [Abstract][Full Text] [Related]
9. Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy.
Bruyniks N; Biglia N; Palacios S; Mueck AO
Climacteric; 2017 Jun; 20(3):195-204. PubMed ID: 28267367
[TBL] [Abstract][Full Text] [Related]
10. Different local estrogen therapies for a tailored approach to GSM.
Nappi RE; Tiranini L; Martini E; Bosoni D; Cassani C; Cucinella L
Climacteric; 2023 Aug; 26(4):361-366. PubMed ID: 37318030
[TBL] [Abstract][Full Text] [Related]
11. Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy.
Mariani L; Gadducci A; Vizza E; Tomao S; Vici P
Gynecol Endocrinol; 2013 Jan; 29(1):25-9. PubMed ID: 22994445
[TBL] [Abstract][Full Text] [Related]
12. Management of genitourinary syndrome of menopause in breast cancer survivors: An update.
Lubián López DM
World J Clin Oncol; 2022 Feb; 13(2):71-100. PubMed ID: 35316932
[TBL] [Abstract][Full Text] [Related]
13. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society.
Menopause; 2013 Sep; 20(9):888-902; quiz 903-4. PubMed ID: 23985562
[TBL] [Abstract][Full Text] [Related]
14. [Local estrogen therapy--clinical implications--2012 update].
Kokot-Kierepa M; Bartuzi A; Kulik-Rechberger B; Rechberger T
Ginekol Pol; 2012 Oct; 83(10):772-7. PubMed ID: 23383564
[TBL] [Abstract][Full Text] [Related]
15. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.
Melisko ME; Goldman ME; Hwang J; De Luca A; Fang S; Esserman LJ; Chien AJ; Park JW; Rugo HS
JAMA Oncol; 2017 Mar; 3(3):313-319. PubMed ID: 27832260
[TBL] [Abstract][Full Text] [Related]
16. New developments in the management of vulvovaginal atrophy: a comprehensive overview.
Donders GGG; Donders FHWV
Expert Opin Pharmacother; 2023 Apr; 24(5):599-616. PubMed ID: 36951262
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial.
Hirschberg AL; Sánchez-Rovira P; Presa-Lorite J; Campos-Delgado M; Gil-Gil M; Lidbrink E; Suárez-Almarza J; Nieto-Magro C
Menopause; 2020 May; 27(5):526-534. PubMed ID: 32049923
[TBL] [Abstract][Full Text] [Related]
18. No increase in incidence or risk of recurrence of breast cancer in ospemifene-treated patients with vulvovaginal atrophy (VVA).
Cai B; Simon J; Villa P; Biglia N; Panay N; Djumaeva S; Particco M; Kanakamedala H; Altomare C
Maturitas; 2020 Dec; 142():38-44. PubMed ID: 33158486
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, tolerability, and endometrial safety of ospemifene compared with current therapies for the treatment of vulvovaginal atrophy: a systematic literature review and network meta-analysis.
Simon JA; Ferenczy A; Black D; Castonguay A; Royer C; Marouf R; Beauchemin C
Menopause; 2023 Aug; 30(8):855-866. PubMed ID: 37369079
[TBL] [Abstract][Full Text] [Related]
20. Hormonal, metabolic, and endometrial safety of testosterone vaginal cream versus estrogens for the treatment of vulvovaginal atrophy in postmenopausal women: a randomized, placebo-controlled study.
Fernandes T; Pedro AO; Baccaro LF; Costa-Paiva LH
Menopause; 2018 Jun; 25(6):641-647. PubMed ID: 29462095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
